<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00307151</url>
  </required_header>
  <id_info>
    <org_study_id>IMPAACT P1060</org_study_id>
    <secondary_id>U01AI068632</secondary_id>
    <nct_id>NCT00307151</nct_id>
  </id_info>
  <brief_title>Antiviral Responses to NNRTI-Based vs. PI-Based ARV Therapy in HIV Infected Infants Who Have or Have Not Received Single Dose NVP for Prevention of Mother-to-Child Transmission of HIV</brief_title>
  <acronym>P1060</acronym>
  <official_title>Phase II, Parallel, Randomized, Clinical Trials Comparing the Responses to Initiation of NNRTI-Based Versus PI-Based Antiretroviral Therapy in HIV Infected Infants Who Have and Have Not Previously Received Single Dose Nevirapine for Prevention of Mother-to-Child HIV Transmission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Maternal Pediatric Adolescent AIDS Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>International Maternal Pediatric Adolescent AIDS Clinical Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single dose of nevirapine (SD NVP) given to an HIV infected pregnant woman followed by a
      single dose to her infant has been shown to be an effective way of reducing the risk of
      mother-to-child transmission (MTCT) of HIV. The purpose of this study was to compare the
      effectiveness of a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based
      antiretroviral regimen versus a protease inhibitor (PI)-based regimen in HIV infected infants
      who had or had not been exposed to SD NVP for prevention of MTCT.

      &gt;&gt;

      &gt;&gt; A five year follow up has been added to the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single dose nevirapine (SD NVP) has greatly reduced the rate of mother-to-child transmission
      (MTCT) of HIV. Non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens are
      recommended for use by the World Health Organization (WHO) in resource-limited settings.
      However, research suggests that mothers and infants exposed to SD NVP experience higher
      virologic failure rates when treated with NNRTI-based regimens than their unexposed
      counterparts. Data show that the use of SD NVP is associated with NNRTI resistance in HIV
      infected women and infants. The purpose of this trial was to compare and evaluate virologic
      responses to an NNRTI-based regimen versus a protease-inhibitor (PI)-based regimen in HIV
      infected infants who had or had not been exposed to SD NVP intrapartum and after birth.

      &gt;&gt;

      &gt;&gt; Participants were enrolled into one of two Cohorts with proposed enrollment into each
      Cohort of 288 participants. Cohort I participants must have received SD NVP for prevention of
      MTCT. Cohort II participants and their mothers must not have previously received NVP or any
      other NNRTIs. Participants in both Cohorts were randomly assigned to receive either an NNRTI
      (Coh I:NVP and Coh II: NVP) or PI (Coh I: LPV/r and Coh II: LPV/r) -based regimen. The
      NNRTI-based regimen included NVP, zidovudine (ZDV) and lamivudine (3TC). The PI-based regimen
      included lopinavir/ritonavir (LPV/r), ZDV and 3TC. If participants experienced adverse
      reactions to ZDV, stavudine (d4T) could be substituted. Randomization was stratified by age
      (6-&lt;12 months vs. &gt;=12 months, with the 2-&lt;6 month stratum added in protocol version 4.0 when
      the lower age limit was decreased from 6 months to 2 months).

      &gt;&gt;

      &gt;&gt; Study visits were scheduled at entry, weeks 2, 4, 8, 12, 16, 24 and then every 24 weeks. A
      physical exam, blood collection, and assessments of HIV-related symptoms occurred at all
      visits.

      &gt;&gt;

      &gt;&gt; Based on a Data Safety and Monitoring Committee (DSMB) review of study data on April 20
      2009, enrollment to Cohort I was closed and interim results released. Data from this and
      another similar study (AIDS Clinical Trials Group (ACTG) A5208) conducted in mothers, showed
      that the PI-based regimen was more effective than the NNRTI-based regimen in infants who had
      received SD NVP for prevention of MTCT. Cohort II was allowed to remain open for enrollment
      and the lower age limit for enrollment reduced from 6 months to 2 months.

      &gt;&gt;

      &gt;&gt; In June 2010, follow-up for all subjects was extended from the original 24 weeks beyond
      enrollment of the last subject to 48 weeks. On October 27 2010, the DSMB conducted a final
      review of Cohort II data, and recommended results be unblinded and released. As found in
      Cohort I, the PI-based regimen was more effective than the NNRTI-based regimen in infants who
      had not been previously exposed to SD NVP for PMTCT. Primary and secondary outcome results
      for Cohort I include all follow-up until April 20, 2009 and for Cohort II, all follow-up
      until October 27, 2010.

      &gt;&gt;

      &gt;&gt; Version 5.0 of the protocol (March 21, 2011) extended follow-up on all subjects for an
      additional 5 years to December 2016. The purpose of the extension was to collect long term
      safety and virologic efficacy data in this study population and to pilot administration of a
      series of neuropsychological tests. During the extension, participants did not receive any
      medications through the study, but instead through their local clinics. Clinic visits took
      place every 3 months. Adverse event summaries use all follow-up in both Cohorts until
      December, 2016.

      &gt;&gt;

      &gt;&gt;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Participants With Treatment Failure, Defined as a Confirmed Virologic Failure or Permanent Discontinuation of the Randomized NNRTI or PI Component of Study Treatment</measure>
    <time_frame>Earlier of 24 weeks or date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009; Coh II: October 27, 2010)</time_frame>
    <description>Treatment failure is defined as a confirmed plasma HIV-1 RNA level that is &lt;1 log10 copies/mL below the study entry value at 12 to 24 weeks after treatment is initiated OR a confirmed plasma HIV-1 RNA level &gt;400 copies/mL at 24 weeks OR permanent discontinuation of the randomized NNRTI or PI component of study treatment at or prior to 24 weeks of treatment for any reason including death. Results report percent of participants reaching a treatment failure endpoint by week 24 calculated using the Kaplan-Meier method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time From Randomization to Treatment Failure, Defined as Virologic Failure or Permanent Discontinuation of the Randomized NNRTI or PI Component of Study Treatment</measure>
    <time_frame>Until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009 - median follow-up 48 weeks and range 0 - 125 weeks; Coh II: October 27, 2010 - median follow-up 72 weeks and range from 0 to 204 weeks)</time_frame>
    <description>Treatment failure is defined as a confirmed plasma HIV-1 RNA level that is &lt;1 log10 copies/mL below the study entry value at 12 to 24 weeks after treatment is initiated OR a confirmed plasma HIV-1 RNA level &gt;400 copies/mL at 24 weeks OR a confirmed viral rebound &gt;4000 copies/mL after week 24 OR permanent discontinuation of the randomized NNRTI or PI component of study treatment for any reason including death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Experiencing Virologic Failure</measure>
    <time_frame>Earlier of 24 weeks or date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009; Coh II: October 27, 2010)</time_frame>
    <description>Virologic failure is defined as a confirmed plasma HIV-1 RNA level that is &lt;1 log10 copies/mL below the study entry value at 12 to 24 weeks after treatment is initiated OR a confirmed plasma HIV-1 RNA level &gt;400 copies/mL at 24 weeks OR death on or before 24 weeks. Results report percent of participants reaching a virologic failure endpoint by week 24 calculated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Randomization to Virologic Failure</measure>
    <time_frame>Until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009 - median follow-up 48 weeks and range 0 - 125 weeks; Coh II: October 27, 2010 - median follow-up 72 weeks and range from 0 to 204 weeks)</time_frame>
    <description>Virologic failure is defined as the earlier of a confirmed plasma HIV-1 RNA level that is &lt;1 log10 copies/mL below the study entry value at 12 to 24 weeks after treatment is initiated OR a confirmed plasma HIV-1 RNA level &gt;400 copies/mL at 24 weeks OR a confirmed viral rebound &gt;4000 copies/mL after week 24 OR death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Start of Study Treatment to First New Grade &gt;=3 Lab Abnormality, Sign or Symptom Occurring on Study Treatment</measure>
    <time_frame>On randomized NNRTI or PI component of study treatment and until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009; Coh II: October 27, 2010)</time_frame>
    <description>Safety events include lab abnormalities, signs or symptoms of grade 3 or higher. Events were graded according to the Division of AIDS Table for Grading Severity of Adult and Pediatric Adverse Events, Version 1.0. Events defined as new if first occurrence was after initiation of study treatment or if severity increased from entry and while on the NNRTI or PI component of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Developing New NRTI, NNRTI or PI-resistant Virus</measure>
    <time_frame>Until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009 - median follow-up 48 weeks and range 0 - 125 weeks; Coh II: October 27, 2010 - median follow-up 72 weeks and range from 0 to 204 weeks)</time_frame>
    <description>Numbers of participants developing new NRTI, NNRTI or PI-resistant virus after reaching a virologic failure endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4 Percent From Entry to Week 48</measure>
    <time_frame>48 weeks if before date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009; Coh II: October 27, 2010)</time_frame>
    <description>Change was calculated as CD4 percent at week 48 minus entry CD4 percent (last CD4 percent before randomization date). Only subjects who reached 48 weeks of follow-up before DSMB decisions to unblind each Cohort were included in summary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Randomization to HIV-related Disease Progression or Death</measure>
    <time_frame>Until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009 - median follow-up 48 weeks and range 0 - 125 weeks; Coh II: October 27, 2010 - median follow-up 72 weeks and range from 0 to 204 weeks)</time_frame>
    <description>HIV-related disease progression was defined as progression in WHO clinical stage from stage at entry or death. For subjects in WHO Stage IV at entry, disease progression was defined as death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Randomization to Death</measure>
    <time_frame>Until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009 - median follow-up 48 weeks and range 0 - 125 weeks; Coh II: October 27, 2010 - median follow-up 72 weeks and range from 0 to 204 weeks)</time_frame>
    <description>Results report 2nd percentile of time from randomization to death</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">452</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Coh I: NVP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort I: Previously received single dose nevirapine (SD NVP). Randomly assigned to receive an NNRTI-based regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Coh I: LPV/r</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort I: Previously received SD NVP. Randomly assigned to receive a PI-based regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Coh II: NVP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort II: Did not previously receive SD NVP. Randomly assigned to receive an NNRTI-based regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Coh II: LPV/r</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort II: Did not previously receive SD NVP. Randomly assigned to receive a PI-based regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>4 mg/kg twice daily</description>
    <arm_group_label>Coh I: NVP</arm_group_label>
    <arm_group_label>Coh I: LPV/r</arm_group_label>
    <arm_group_label>Coh II: NVP</arm_group_label>
    <arm_group_label>Coh II: LPV/r</arm_group_label>
    <other_name>3TC</other_name>
    <other_name>Epivir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/ritonavir</intervention_name>
    <description>16/4 mg/kg twice daily for participants 2 months of age to less than 6 months of age; 12/3 mg/kg twice daily for participants at least 6 months of age and weighing less than 15 kg; 10/2.5 mg/kg twice daily for participants at least 6 months of age and weighing between 15 kg and 40kg; 400/100 mg twice daily for participants weighing more than 40 kg</description>
    <arm_group_label>Coh I: LPV/r</arm_group_label>
    <arm_group_label>Coh II: LPV/r</arm_group_label>
    <other_name>LPV/r</other_name>
    <other_name>Kaletra</other_name>
    <other_name>LPV/RTV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
    <description>Initially: 4 mg/kg for 14 days, then 7 mg/kg twice daily. In protocol version 2.0, Letter of Amendment 1 (September 2007), NVP dose increased to conform with WHO guidelines to: 160 to 200 mg/m^2/dose to max 200 mg once daily for 14 days, then 160 to 200 mg/m^2/dose to max 200 mg twice daily</description>
    <arm_group_label>Coh I: NVP</arm_group_label>
    <arm_group_label>Coh II: NVP</arm_group_label>
    <other_name>NVP</other_name>
    <other_name>Viramune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
    <description>180 mg/m^2 twice daily</description>
    <arm_group_label>Coh I: NVP</arm_group_label>
    <arm_group_label>Coh I: LPV/r</arm_group_label>
    <arm_group_label>Coh II: NVP</arm_group_label>
    <arm_group_label>Coh II: LPV/r</arm_group_label>
    <other_name>ZDV</other_name>
    <other_name>AZT</other_name>
    <other_name>Retrovir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for All Participants:

          -  age &gt;=6 months to &lt; 36 months (decreased to 2 months in protocol version 4.0)

          -  HIV infected

          -  Viral load greater than 5,000 copies/ml within 60 days of study entry

          -  Treatment naive except for antiretrovirals (ARV) used to prevent MTCT (infant ARV use
             for &lt;=1 week postpartum for prevention of MTCT allowed)

          -  Eligible for treatment according to WHO pediatric algorithm (updated in protocol
             version 1.0, Letter of amendment (LOA)#1) and protocol version 2.0, LOA#3). Subjects
             with active opportunistic infections were not eligible for study participation until
             they had been treated and were clinically stable

          -  Parent or legal guardian willing to provide signed informed consent

        Inclusion Criteria for Cohort I:

          -  Documentation of maternal or infant NVP exposure or a highly reliable verbal report.
             (Updated in protocol version 2.0, LOA#3 to require written clinic/hospital
             documentation of infant exposure to SD NVP)

          -  Use of maternal ARV, including NVP, permitted during pregnancy

          -  One or more of the following: strict formula feeding, initial infant HIV diagnosis
             occurring while younger than 60 days of age, or an initial AIDS-defining illness
             diagnosis by WHO criteria while younger than 60 days of age.

        Inclusion Criteria for Cohort II:

        &gt;&gt;

          -  Use of maternal ARVs, excluding NNRTIs, permitted during pregnancy

          -  Evidence of lack of prior NVP exposure (added in protocol version 2.0, LOA#3) by
             review of maternal and child medical records or health card (or other written
             documentation) for evidence of NVP exposure to mother or infant during pregnancy,
             labor, and delivery. If no written documentation showing lack of NVP use was shown in
             these records or if these records were not available for review, then a verbal report
             considered to be highly reliable by the study nurse was acceptable AND one or more of
             the following:

               1. Study subject born before single dose NVP was available for prevention of MTCT of
                  HIV in the location of birth of study subject

                  &gt;&gt;

               2. Study subject born before the biological mother's first positive HIV test

                  &gt;&gt;

               3. Site staff had another reason to believe the subject had not been exposed to NVP

                  &gt;&gt;

                  &gt;&gt;

        Exclusion Criteria for All Participants:

          -  Grade 2 or higher aspartate aminotransferase (AST) or alanine aminotransferase (ALT)
             at study screening &gt;&gt;

          -  Grade 3 or higher laboratory toxicity at study screening &gt;&gt;

          -  Received ARVs for anything other than the prevention of intrapartum MTCT. Infants who
             received ARVs after the first week of life (e.g., for the prevention of MTCT of HIV
             through breastfeeding) were excluded

          -  Acute serious infections requiring active treatment. Subjects could be receiving
             treatment for active TB if it did not include rifamycin drugs

          -  Receiving chemotherapy for an active tumor &gt;&gt;

          -  History of a cardiac conduction abnormality and underlying structural heart disease

          -  Required certain medications

        Exclusion Criteria for Cohort I:

          -  History of or currently breastfeeding. Breastfed infants with a positive HIV test or
             who had experienced an AIDS-defining illness by WHO criteria at 60 days of age or
             younger were not excluded

        Exclusion Criteria for Cohort II:

          -  Exposure to any maternal NVP or other NNRTI prior to or during the pregnancy or while
             breastfeeding

          -  Exposure of infant to NVP at any time including during the first week of life
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>36 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Palumbo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Division of Infectious Diseases and International Health, Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Avy Violari, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Perinatal HIV Research Unit, University of Witwatersrand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BJ Medical College CRS</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Lilongwe CRS</name>
      <address>
        <city>Mzimba Road</city>
        <state>Lilongwe</state>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nelson R. Mandela School of Medicine, University of Kwazulu</name>
      <address>
        <city>Natal</city>
        <state>Durban</state>
        <zip>50202</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Stellenbosch-Tygerberg Hospital, South Africa</name>
      <address>
        <city>Cape Town</city>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harriet Shezi Clinic at Chris Hani Baragwanath Hospital</name>
      <address>
        <city>Johannesburg</city>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kilimanjaro Christian Medical CRS</name>
      <address>
        <city>IDC Research Offices</city>
        <state>Moshi</state>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Makerere University</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Clinic CRS</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ-College of Health Sciences</name>
      <address>
        <city>Harare</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>Malawi</country>
    <country>South Africa</country>
    <country>Tanzania</country>
    <country>Uganda</country>
    <country>Zambia</country>
    <country>Zimbabwe</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Arriv√© E, Newell ML, Ekouevi DK, Chaix ML, Thiebaut R, Masquelier B, Leroy V, Perre PV, Rouzioux C, Dabis F; Ghent Group on HIV in Women and Children. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol. 2007 Oct;36(5):1009-21. Epub 2007 May 28. Review.</citation>
    <PMID>17533166</PMID>
  </reference>
  <reference>
    <citation>Chi BH, Sinkala M, Stringer EM, Cantrell RA, Mtonga V, Bulterys M, Zulu I, Kankasa C, Wilfert C, Weidle PJ, Vermund SH, Stringer JS. Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine. AIDS. 2007 May 11;21(8):957-64.</citation>
    <PMID>17457089</PMID>
  </reference>
  <reference>
    <citation>Eshleman SH, Hoover DR, Hudelson SE, Chen S, Fiscus SA, Piwowar-Manning E, Jackson JB, Kumwenda NI, Taha TE. Development of nevirapine resistance in infants is reduced by use of infant-only single-dose nevirapine plus zidovudine postexposure prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Infect Dis. 2006 Feb 15;193(4):479-81. Epub 2006 Jan 11.</citation>
    <PMID>16425125</PMID>
  </reference>
  <reference>
    <citation>White PD. What causes prolonged fatigue after infectious mononucleosis: and does it tell us anything about chronic fatigue syndrome? J Infect Dis. 2007 Jul 1;196(1):4-5. Epub 2007 May 24.</citation>
    <PMID>17538875</PMID>
  </reference>
  <reference>
    <citation>Sankatsing RR, Wit FW, Pakker N, Vyankandondera J, Mmiro F, Okong P, Kastelein JJ, Lange JM, Stroes ES, Reiss P. Effects of nevirapine, compared with lamivudine, on lipids and lipoproteins in HIV-1-uninfected newborns: the stopping infection from mother-to-child via breast-feeding in Africa lipid substudy. J Infect Dis. 2007 Jul 1;196(1):15-22. Epub 2007 May 16.</citation>
    <PMID>17538878</PMID>
  </reference>
  <results_reference>
    <citation>Palumbo P, Lindsey JC, Hughes MD, Cotton MF, Bobat R, Meyers T, Bwakura-Dangarembizi M, Chi BH, Musoke P, Kamthunzi P, Schimana W, Purdue L, Eshleman SH, Abrams EJ, Millar L, Petzold E, Mofenson LM, Jean-Philippe P, Violari A. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med. 2010 Oct 14;363(16):1510-20. doi: 10.1056/NEJMoa1000931.</citation>
    <PMID>20942667</PMID>
  </results_reference>
  <results_reference>
    <citation>Palumbo P, Violari A, Lindsey J, Hughes M, Jean-Philippe P, Mofenson L, Purdue L, Eshleman S for the IMPAACT P1060 Study Team. Nevirapine vs Lopinavir-ritonavir-based antiretroviral therapy in single dose Nevirapine-exposed HIV-infected infants: preliminary results from the IMPAACT P1060 Trial. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Capetown, July, 2009.</citation>
  </results_reference>
  <results_reference>
    <citation>Palumbo P, Violari A, Lindsey J, Hughes M, Jean-Philippe P, Mofenson L, Bwakura-Dangarembizi M, Kamthunzi P, Eshleman S and Prudue L for the IMPAACT P1060 Team. Nevirapine (NVP)-vs. Lopinavir-Ritonavir (LPV/r)-based antiretroviral therapy (ART) among HIV-infected infants in resource-limited settings: The IMPAACT P1060 Trial. 18th Conference on Retroviruses and Opportunistic Infections, Boston, February, 2011.</citation>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2006</study_first_submitted>
  <study_first_submitted_qc>March 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2006</study_first_posted>
  <results_first_submitted>July 5, 2011</results_first_submitted>
  <results_first_submitted_qc>July 5, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 3, 2011</results_first_posted>
  <last_update_submitted>March 15, 2017</last_update_submitted>
  <last_update_submitted_qc>March 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment Naive</keyword>
  <keyword>Mother-To-Child Transmission</keyword>
  <keyword>MTCT</keyword>
  <keyword>Pediatrics</keyword>
  <keyword>Viral resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study participants were recruited at 10 study sites, 4 in South Africa and 1 each in Uganda, Zimbabwe, Zambia, Malawi, Tanzania and India between November 9, 2006 and March 19, 2010.</recruitment_details>
      <pre_assignment_details>Infants and children 6 - 36 months of age (lower age limit changed to 2 months in Protocol Version 4.0) were stratified by age (2-&lt;6 months, 6-&lt;12 months and &gt;=12 months) and randomly assigned to receive either AZT/3TC/NVP or AZT/3TC/LPV/r. One subject was randomized but never started study treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Coh I: NVP</title>
          <description>Cohort I: Previously received single dose nevirapine (SD NVP). Randomly assigned to receive an NNRTI-based regimen.</description>
        </group>
        <group group_id="P2">
          <title>Coh I: LPV/r</title>
          <description>Cohort I: Previously received SD NVP. Randomly assigned to receive a PI-based regimen.</description>
        </group>
        <group group_id="P3">
          <title>Coh II: NVP</title>
          <description>Cohort II: Did not previously receive SD NVP. Randomly assigned to receive an NNRTI-based regimen</description>
        </group>
        <group group_id="P4">
          <title>Coh II: LPV/r</title>
          <description>Cohort II: Did not previously receive SD NVP. Randomly assigned to receive a PI-based regimen</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="82"/>
                <participants group_id="P3" count="147"/>
                <participants group_id="P4" count="140">One participant never started treatment, were not followed and not included in analysis.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71">Results are through date DSMB closed Cohort I to accrual (April 20, 2009)</participants>
                <participants group_id="P2" count="75">Results are through date DSMB closed Cohort I to accrual (April 20, 2009)</participants>
                <participants group_id="P3" count="127">Results are through date DSMB recommended Cohort II results be unblinded (October 27, 2010)</participants>
                <participants group_id="P4" count="129">Results are through date DSMB recommended Cohort II results be unblinded (October 27, 2010)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Severe debilitation, unable to continue</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject unable to get to clinic</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not willing to adhere to study reqs</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinic unable to contact subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Coh I: NVP</title>
          <description>Cohort I: Previously received single dose nevirapine (SD NVP). Randomly assigned to receive an NNRTI-based regimen.</description>
        </group>
        <group group_id="B2">
          <title>Coh I: LPV/r</title>
          <description>Cohort I: Previously received SD NVP. Randomly assigned to receive a PI-based regimen.</description>
        </group>
        <group group_id="B3">
          <title>Coh II: NVP</title>
          <description>Cohort II: Did not previously receive SD NVP. Randomly assigned to receive an NNRTI-based regimen</description>
        </group>
        <group group_id="B4">
          <title>Coh II: LPV/r</title>
          <description>Cohort II: Did not previously receive SD NVP. Randomly assigned to receive a PI-based regimen</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="82"/>
            <count group_id="B2" value="82"/>
            <count group_id="B3" value="147"/>
            <count group_id="B4" value="140"/>
            <count group_id="B5" value="451"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="106"/>
                    <measurement group_id="B4" value="104"/>
                    <measurement group_id="B5" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="72"/>
                    <measurement group_id="B5" value="237"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="68"/>
                    <measurement group_id="B5" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Black African</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="132"/>
                    <measurement group_id="B4" value="134"/>
                    <measurement group_id="B5" value="428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coloured</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native of India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Tanzania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Zambia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uganda</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malawi</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Zimbabwe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ever breastfed</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="118"/>
                    <measurement group_id="B4" value="115"/>
                    <measurement group_id="B5" value="267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Documentation of SD NVP use at birth</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Born before NVP available/mother known to have HIV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="116"/>
                    <measurement group_id="B4" value="104"/>
                    <measurement group_id="B5" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medical record review</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Verbal evidence only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Found to have received SD NVP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>WHO Stage</title>
          <description>World Health Organization (WHO) staging system for HIV infection and disease.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="77"/>
                    <measurement group_id="B5" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV-1 RNA</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;100,000 copies/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100,000 - &lt; 750,000 copies/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=750,000 copies/ml</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="60"/>
                    <measurement group_id="B5" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 Percent</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;15 Percent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="69"/>
                    <measurement group_id="B5" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 Percent - &lt; 25 Percent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="54"/>
                    <measurement group_id="B5" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 25 Percent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NVP resistance</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="110"/>
                    <measurement group_id="B4" value="91"/>
                    <measurement group_id="B5" value="331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants With Treatment Failure, Defined as a Confirmed Virologic Failure or Permanent Discontinuation of the Randomized NNRTI or PI Component of Study Treatment</title>
        <description>Treatment failure is defined as a confirmed plasma HIV-1 RNA level that is &lt;1 log10 copies/mL below the study entry value at 12 to 24 weeks after treatment is initiated OR a confirmed plasma HIV-1 RNA level &gt;400 copies/mL at 24 weeks OR permanent discontinuation of the randomized NNRTI or PI component of study treatment at or prior to 24 weeks of treatment for any reason including death. Results report percent of participants reaching a treatment failure endpoint by week 24 calculated using the Kaplan-Meier method.</description>
        <time_frame>Earlier of 24 weeks or date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009; Coh II: October 27, 2010)</time_frame>
        <population>Analysis uses intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Coh I: NVP</title>
            <description>Cohort I: Previously received single dose nevirapine (SD NVP). Randomly assigned to receive an NNRTI-based regimen.</description>
          </group>
          <group group_id="O2">
            <title>Coh I: LPV/r</title>
            <description>Cohort I: Previously received SD NVP. Randomly assigned to receive a PI-based regimen.</description>
          </group>
          <group group_id="O3">
            <title>Coh II: NVP</title>
            <description>Cohort II: Did not previously receive SD NVP. Randomly assigned to receive an NNRTI-based regimen</description>
          </group>
          <group group_id="O4">
            <title>Coh II: LPV/r</title>
            <description>Cohort II: Did not previously receive SD NVP. Randomly assigned to receive a PI-based regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Treatment Failure, Defined as a Confirmed Virologic Failure or Permanent Discontinuation of the Randomized NNRTI or PI Component of Study Treatment</title>
          <description>Treatment failure is defined as a confirmed plasma HIV-1 RNA level that is &lt;1 log10 copies/mL below the study entry value at 12 to 24 weeks after treatment is initiated OR a confirmed plasma HIV-1 RNA level &gt;400 copies/mL at 24 weeks OR permanent discontinuation of the randomized NNRTI or PI component of study treatment at or prior to 24 weeks of treatment for any reason including death. Results report percent of participants reaching a treatment failure endpoint by week 24 calculated using the Kaplan-Meier method.</description>
          <population>Analysis uses intent to treat population</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="147"/>
                <count group_id="O4" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.6"/>
                    <measurement group_id="O2" value="21.7"/>
                    <measurement group_id="O3" value="40.8"/>
                    <measurement group_id="O4" value="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <p_value_desc>P-value not adjusted for multiple interim analyses, but adjustment would be negligible because Peto-Haybittle spending function used as basis for calculating repeated confidence intervals used in interim monitoring.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Risk difference estimate stratified by age (&lt;12 months vs. &gt;=12 months)and reports rate on NVP arm minus rate on LPV/r arm</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>18.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.7</ci_lower_limit>
            <ci_upper_limit>33.6</ci_upper_limit>
            <estimate_desc>Endpoint rates with standard errors calculated from Kaplan-Meier curves for each treatment group and age stratum. Differences in week 24 failure proportions by treatment calculated weighted by the inverse of the variance in each age stratum.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value not adjusted for multiple interim analyses, but adjustment would be negligible because Peto-Haybittle spending function used as basis for calculating repeated confidence intervals used in interim monitoring.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Risk difference estimate stratified by age (&lt;12 months vs. &gt;=12 months) and reports rate on NVP arm minus rate on LPV/r arm</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>21.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.2</ci_lower_limit>
            <ci_upper_limit>31.8</ci_upper_limit>
            <estimate_desc>Endpoint rates with standard errors calculated from Kaplan-Meier curves for each treatment group and age stratum. Differences in week 24 failure proportions by treatment calculated weighted by the inverse of the variance in each age stratum.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Randomization to Treatment Failure, Defined as Virologic Failure or Permanent Discontinuation of the Randomized NNRTI or PI Component of Study Treatment</title>
        <description>Treatment failure is defined as a confirmed plasma HIV-1 RNA level that is &lt;1 log10 copies/mL below the study entry value at 12 to 24 weeks after treatment is initiated OR a confirmed plasma HIV-1 RNA level &gt;400 copies/mL at 24 weeks OR a confirmed viral rebound &gt;4000 copies/mL after week 24 OR permanent discontinuation of the randomized NNRTI or PI component of study treatment for any reason including death.</description>
        <time_frame>Until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009 - median follow-up 48 weeks and range 0 - 125 weeks; Coh II: October 27, 2010 - median follow-up 72 weeks and range from 0 to 204 weeks)</time_frame>
        <population>Analysis uses intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Coh I: NVP</title>
            <description>Cohort I: Previously received single dose nevirapine (SD NVP). Randomly assigned to receive an NNRTI-based regimen.</description>
          </group>
          <group group_id="O2">
            <title>Coh I: LPV/r</title>
            <description>Cohort I: Previously received SD NVP. Randomly assigned to receive a PI-based regimen.</description>
          </group>
          <group group_id="O3">
            <title>Coh II: NVP</title>
            <description>Cohort II: Did not previously receive SD NVP. Randomly assigned to receive an NNRTI-based regimen</description>
          </group>
          <group group_id="O4">
            <title>Coh II: LPV/r</title>
            <description>Cohort II: Did not previously receive SD NVP. Randomly assigned to receive a PI-based regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Randomization to Treatment Failure, Defined as Virologic Failure or Permanent Discontinuation of the Randomized NNRTI or PI Component of Study Treatment</title>
          <description>Treatment failure is defined as a confirmed plasma HIV-1 RNA level that is &lt;1 log10 copies/mL below the study entry value at 12 to 24 weeks after treatment is initiated OR a confirmed plasma HIV-1 RNA level &gt;400 copies/mL at 24 weeks OR a confirmed viral rebound &gt;4000 copies/mL after week 24 OR permanent discontinuation of the randomized NNRTI or PI component of study treatment for any reason including death.</description>
          <population>Analysis uses intent to treat population</population>
          <units>Weeks</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="147"/>
                <count group_id="O4" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>10th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="4" upper_limit="12"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="16"/>
                    <measurement group_id="O3" value="4" lower_limit="2" upper_limit="8"/>
                    <measurement group_id="O4" value="14" lower_limit="8" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="12" upper_limit="24"/>
                    <measurement group_id="O2" value="36" lower_limit="16">Not estimable as upper limit for survival function at all weeks is above 75%</measurement>
                    <measurement group_id="O3" value="16" lower_limit="12" upper_limit="24"/>
                    <measurement group_id="O4" value="36" lower_limit="24" upper_limit="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Experiencing Virologic Failure</title>
        <description>Virologic failure is defined as a confirmed plasma HIV-1 RNA level that is &lt;1 log10 copies/mL below the study entry value at 12 to 24 weeks after treatment is initiated OR a confirmed plasma HIV-1 RNA level &gt;400 copies/mL at 24 weeks OR death on or before 24 weeks. Results report percent of participants reaching a virologic failure endpoint by week 24 calculated using the Kaplan-Meier method.</description>
        <time_frame>Earlier of 24 weeks or date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009; Coh II: October 27, 2010)</time_frame>
        <population>Analysis uses intent to treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Coh I: NVP</title>
            <description>Cohort I: Previously received single dose nevirapine (SD NVP). Randomly assigned to receive an NNRTI-based regimen.</description>
          </group>
          <group group_id="O2">
            <title>Coh I: LPV/r</title>
            <description>Cohort I: Previously received SD NVP. Randomly assigned to receive a PI-based regimen.</description>
          </group>
          <group group_id="O3">
            <title>Coh II: NVP</title>
            <description>Cohort II: Did not previously receive SD NVP. Randomly assigned to receive an NNRTI-based regimen</description>
          </group>
          <group group_id="O4">
            <title>Coh II: LPV/r</title>
            <description>Cohort II: Did not previously receive SD NVP. Randomly assigned to receive a PI-based regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Experiencing Virologic Failure</title>
          <description>Virologic failure is defined as a confirmed plasma HIV-1 RNA level that is &lt;1 log10 copies/mL below the study entry value at 12 to 24 weeks after treatment is initiated OR a confirmed plasma HIV-1 RNA level &gt;400 copies/mL at 24 weeks OR death on or before 24 weeks. Results report percent of participants reaching a virologic failure endpoint by week 24 calculated using the Kaplan-Meier method.</description>
          <population>Analysis uses intent to treat population.</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="147"/>
                <count group_id="O4" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4"/>
                    <measurement group_id="O2" value="10.4"/>
                    <measurement group_id="O3" value="28.6"/>
                    <measurement group_id="O4" value="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Randomization to Virologic Failure</title>
        <description>Virologic failure is defined as the earlier of a confirmed plasma HIV-1 RNA level that is &lt;1 log10 copies/mL below the study entry value at 12 to 24 weeks after treatment is initiated OR a confirmed plasma HIV-1 RNA level &gt;400 copies/mL at 24 weeks OR a confirmed viral rebound &gt;4000 copies/mL after week 24 OR death.</description>
        <time_frame>Until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009 - median follow-up 48 weeks and range 0 - 125 weeks; Coh II: October 27, 2010 - median follow-up 72 weeks and range from 0 to 204 weeks)</time_frame>
        <population>Analysis uses intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Coh I: NVP</title>
            <description>Cohort I: Previously received single dose nevirapine (SD NVP). Randomly assigned to receive an NNRTI-based regimen.</description>
          </group>
          <group group_id="O2">
            <title>Coh I: LPV/r</title>
            <description>Cohort I: Previously received SD NVP. Randomly assigned to receive a PI-based regimen.</description>
          </group>
          <group group_id="O3">
            <title>Coh II: NVP</title>
            <description>Cohort II: Did not previously receive SD NVP. Randomly assigned to receive an NNRTI-based regimen</description>
          </group>
          <group group_id="O4">
            <title>Coh II: LPV/r</title>
            <description>Cohort II: Did not previously receive SD NVP. Randomly assigned to receive a PI-based regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Randomization to Virologic Failure</title>
          <description>Virologic failure is defined as the earlier of a confirmed plasma HIV-1 RNA level that is &lt;1 log10 copies/mL below the study entry value at 12 to 24 weeks after treatment is initiated OR a confirmed plasma HIV-1 RNA level &gt;400 copies/mL at 24 weeks OR a confirmed viral rebound &gt;4000 copies/mL after week 24 OR death.</description>
          <population>Analysis uses intent to treat population</population>
          <units>Weeks</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="147"/>
                <count group_id="O4" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="4" upper_limit="12"/>
                    <measurement group_id="O2" value="16" lower_limit="2" upper_limit="24"/>
                    <measurement group_id="O3" value="12" lower_limit="2" upper_limit="16"/>
                    <measurement group_id="O4" value="16" lower_limit="12" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="12" upper_limit="24"/>
                    <measurement group_id="O2" value="24" lower_limit="12">Not estimable as upper limit for survival function at all weeks above 90%</measurement>
                    <measurement group_id="O3" value="16" lower_limit="12" upper_limit="24"/>
                    <measurement group_id="O4" value="24" lower_limit="16" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Start of Study Treatment to First New Grade &gt;=3 Lab Abnormality, Sign or Symptom Occurring on Study Treatment</title>
        <description>Safety events include lab abnormalities, signs or symptoms of grade 3 or higher. Events were graded according to the Division of AIDS Table for Grading Severity of Adult and Pediatric Adverse Events, Version 1.0. Events defined as new if first occurrence was after initiation of study treatment or if severity increased from entry and while on the NNRTI or PI component of study treatment.</description>
        <time_frame>On randomized NNRTI or PI component of study treatment and until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009; Coh II: October 27, 2010)</time_frame>
        <population>Uses follow-up from start of NVP or LPV/r component of study treatment until component switched or date of DSMB decision to unblind results, whichever occurred first</population>
        <group_list>
          <group group_id="O1">
            <title>Coh I: NVP</title>
            <description>Cohort I: Previously received single dose nevirapine (SD NVP). Randomly assigned to receive an NNRTI-based regimen.</description>
          </group>
          <group group_id="O2">
            <title>Coh I: LPV/r</title>
            <description>Cohort I: Previously received SD NVP. Randomly assigned to receive a PI-based regimen.</description>
          </group>
          <group group_id="O3">
            <title>Coh II: NVP</title>
            <description>Cohort II: Did not previously receive SD NVP. Randomly assigned to receive an NNRTI-based regimen</description>
          </group>
          <group group_id="O4">
            <title>Coh II: LPV/r</title>
            <description>Cohort II: Did not previously receive SD NVP. Randomly assigned to receive a PI-based regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Start of Study Treatment to First New Grade &gt;=3 Lab Abnormality, Sign or Symptom Occurring on Study Treatment</title>
          <description>Safety events include lab abnormalities, signs or symptoms of grade 3 or higher. Events were graded according to the Division of AIDS Table for Grading Severity of Adult and Pediatric Adverse Events, Version 1.0. Events defined as new if first occurrence was after initiation of study treatment or if severity increased from entry and while on the NNRTI or PI component of study treatment.</description>
          <population>Uses follow-up from start of NVP or LPV/r component of study treatment until component switched or date of DSMB decision to unblind results, whichever occurred first</population>
          <units>Weeks</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="147"/>
                <count group_id="O4" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>10th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="2" upper_limit="12"/>
                    <measurement group_id="O2" value="8" lower_limit="2" upper_limit="25"/>
                    <measurement group_id="O3" value="3" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="2" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="12">Not estimable as upper limit for survival function at all weeks above 75%</measurement>
                    <measurement group_id="O2" value="36" lower_limit="14" upper_limit="86"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="6"/>
                    <measurement group_id="O4" value="12" lower_limit="7" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Developing New NRTI, NNRTI or PI-resistant Virus</title>
        <description>Numbers of participants developing new NRTI, NNRTI or PI-resistant virus after reaching a virologic failure endpoint</description>
        <time_frame>Until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009 - median follow-up 48 weeks and range 0 - 125 weeks; Coh II: October 27, 2010 - median follow-up 72 weeks and range from 0 to 204 weeks)</time_frame>
        <population>Results included for any participant who was a virologic failure as defined in secondary outcome 4 and who had results available at study entry and virologic failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Coh I: NVP</title>
            <description>Cohort I: Previously received single dose nevirapine (SD NVP). Randomly assigned to receive an NNRTI-based regimen.</description>
          </group>
          <group group_id="O2">
            <title>Coh I: LPV/r</title>
            <description>Cohort I: Previously received SD NVP. Randomly assigned to receive a PI-based regimen.</description>
          </group>
          <group group_id="O3">
            <title>Coh II: NVP</title>
            <description>Cohort II: Did not previously receive SD NVP. Randomly assigned to receive an NNRTI-based regimen</description>
          </group>
          <group group_id="O4">
            <title>Coh II: LPV/r</title>
            <description>Cohort II: Did not previously receive SD NVP. Randomly assigned to receive a PI-based regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Developing New NRTI, NNRTI or PI-resistant Virus</title>
          <description>Numbers of participants developing new NRTI, NNRTI or PI-resistant virus after reaching a virologic failure endpoint</description>
          <population>Results included for any participant who was a virologic failure as defined in secondary outcome 4 and who had results available at study entry and virologic failure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CD4 Percent From Entry to Week 48</title>
        <description>Change was calculated as CD4 percent at week 48 minus entry CD4 percent (last CD4 percent before randomization date). Only subjects who reached 48 weeks of follow-up before DSMB decisions to unblind each Cohort were included in summary.</description>
        <time_frame>48 weeks if before date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009; Coh II: October 27, 2010)</time_frame>
        <population>Analysis uses intent to treat population. Change reported if subject followed at least 48 weeks before DSMB unblinding of results for each Cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Coh I: NVP</title>
            <description>Cohort I: Previously received single dose nevirapine (SD NVP). Randomly assigned to receive an NNRTI-based regimen.</description>
          </group>
          <group group_id="O2">
            <title>Coh I: LPV/r</title>
            <description>Cohort I: Previously received SD NVP. Randomly assigned to receive a PI-based regimen.</description>
          </group>
          <group group_id="O3">
            <title>Coh II: NVP</title>
            <description>Cohort II: Did not previously receive SD NVP. Randomly assigned to receive an NNRTI-based regimen</description>
          </group>
          <group group_id="O4">
            <title>Coh II: LPV/r</title>
            <description>Cohort II: Did not previously receive SD NVP. Randomly assigned to receive a PI-based regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CD4 Percent From Entry to Week 48</title>
          <description>Change was calculated as CD4 percent at week 48 minus entry CD4 percent (last CD4 percent before randomization date). Only subjects who reached 48 weeks of follow-up before DSMB decisions to unblind each Cohort were included in summary.</description>
          <population>Analysis uses intent to treat population. Change reported if subject followed at least 48 weeks before DSMB unblinding of results for each Cohort</population>
          <units>Percent of CD4</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="109"/>
                <count group_id="O4" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" lower_limit="11.6" upper_limit="16.2"/>
                    <measurement group_id="O2" value="12.0" lower_limit="10.3" upper_limit="13.7"/>
                    <measurement group_id="O3" value="15.2" lower_limit="13.6" upper_limit="16.9"/>
                    <measurement group_id="O4" value="14.3" lower_limit="13.0" upper_limit="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Randomization to HIV-related Disease Progression or Death</title>
        <description>HIV-related disease progression was defined as progression in WHO clinical stage from stage at entry or death. For subjects in WHO Stage IV at entry, disease progression was defined as death.</description>
        <time_frame>Until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009 - median follow-up 48 weeks and range 0 - 125 weeks; Coh II: October 27, 2010 - median follow-up 72 weeks and range from 0 to 204 weeks)</time_frame>
        <population>Analysis uses intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Coh I: NVP</title>
            <description>Cohort I: Previously received single dose nevirapine (SD NVP). Randomly assigned to receive an NNRTI-based regimen.</description>
          </group>
          <group group_id="O2">
            <title>Coh I: LPV/r</title>
            <description>Cohort I: Previously received SD NVP. Randomly assigned to receive a PI-based regimen.</description>
          </group>
          <group group_id="O3">
            <title>Coh II: NVP</title>
            <description>Cohort II: Did not previously receive SD NVP. Randomly assigned to receive an NNRTI-based regimen</description>
          </group>
          <group group_id="O4">
            <title>Coh II: LPV/r</title>
            <description>Cohort II: Did not previously receive SD NVP. Randomly assigned to receive a PI-based regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Randomization to HIV-related Disease Progression or Death</title>
          <description>HIV-related disease progression was defined as progression in WHO clinical stage from stage at entry or death. For subjects in WHO Stage IV at entry, disease progression was defined as death.</description>
          <population>Analysis uses intent to treat population</population>
          <units>Weeks</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="147"/>
                <count group_id="O4" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="2" upper_limit="24"/>
                    <measurement group_id="O2" value="2" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O3" value="8" lower_limit="2" upper_limit="24"/>
                    <measurement group_id="O4" value="35" lower_limit="2" upper_limit="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="5">Not estimable as upper limit of survival function at all weeks above 90%</measurement>
                    <measurement group_id="O2" value="4" lower_limit="2" upper_limit="24"/>
                    <measurement group_id="O3" value="35" lower_limit="8">Not estimable as upper limit of survival function at all weeks above 98%</measurement>
                    <measurement group_id="O4" value="132" lower_limit="35">Not estimable as upper limit of survival function at all weeks above 98%</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Randomization to Death</title>
        <description>Results report 2nd percentile of time from randomization to death</description>
        <time_frame>Until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009 - median follow-up 48 weeks and range 0 - 125 weeks; Coh II: October 27, 2010 - median follow-up 72 weeks and range from 0 to 204 weeks)</time_frame>
        <population>Analysis uses intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Coh I: NVP</title>
            <description>Cohort I: Previously received single dose nevirapine (SD NVP). Randomly assigned to receive an NNRTI-based regimen.</description>
          </group>
          <group group_id="O2">
            <title>Coh I: LPV/r</title>
            <description>Cohort I: Previously received SD NVP. Randomly assigned to receive a PI-based regimen.</description>
          </group>
          <group group_id="O3">
            <title>Coh II: NVP</title>
            <description>Cohort II: Did not previously receive SD NVP. Randomly assigned to receive an NNRTI-based regimen</description>
          </group>
          <group group_id="O4">
            <title>Coh II: LPV/r</title>
            <description>Cohort II: Did not previously receive SD NVP. Randomly assigned to receive a PI-based regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Randomization to Death</title>
          <description>Results report 2nd percentile of time from randomization to death</description>
          <population>Analysis uses intent to treat population</population>
          <units>Weeks</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="147"/>
                <count group_id="O4" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="3" upper_limit="68"/>
                    <measurement group_id="O2" value="3" lower_limit="2">Not estimable as upper limit for survival function at all weeks above 98%</measurement>
                    <measurement group_id="O3" value="2" lower_limit="2" upper_limit="12"/>
                    <measurement group_id="O4" value="83" lower_limit="3">Not estimable as upper limit for survival function at all weeks above 98%</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From study enrollment until study completion</time_frame>
      <desc>Expedited adverse event (AE) reporting followed Intensive Division of AIDS (DAIDS) Reporting Level, which included AEs resulting in death, congenital anomalies, fetal losses, significant disabilities requiring hospitalization and &gt;=grade 3 AEs defined by the &quot;DAIDS Table for Grading the Severity of Adult and Pediatric AEs&quot;, V1.0, 12/2004.</desc>
      <group_list>
        <group group_id="E1">
          <title>Coh I: NVP</title>
          <description>Cohort II: Previously received single dose nevirapine (SD NVP). Randomly assigned to receive an NNRTI-based regimen.</description>
        </group>
        <group group_id="E2">
          <title>Coh I: LPV/r</title>
          <description>Cohort II: Previously received SD NVP. Randomly assigned to receive a PI-based regimen.</description>
        </group>
        <group group_id="E3">
          <title>Coh II: NVP</title>
          <description>Cohort II: Did not previously receive SD NVP. Randomly assigned to receive an NNRTI-based regimen.</description>
        </group>
        <group group_id="E4">
          <title>Coh II: LPV/r</title>
          <description>Cohort II: Did not previously receive SD NVP. Randomly assigned to receive a PI-based regimen.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immunosuppression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Measles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Neutrophil count</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Hypocalcaemic seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Breath holding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="146" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="140" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="68" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Measles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Molluscum contagiosum</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Persistent generalised lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Plasmodium falciparum infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Purulent discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Tinea capitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="54" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Tinea faciei</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Tinea infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="54" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="126" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="113" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="105" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="113" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Kwashiorkor</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="60" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Pharyngeal erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Pharyngeal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Tonsillar hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="86" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="72" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Skin plaque</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Skin reaction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="147"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In accordance with the Clinical Trial Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscript and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Accrual to Cohort I was terminated early by the Data Safety Monitoring Committee after enrollment of 164 of the planned 288 subjects.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Melissa Allen, Director, IMPAACT Operations Center</name_or_title>
      <organization>Family Health International (FHI 360)</organization>
      <phone>(919) 405-1429</phone>
      <email>mallen@fhi360.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

